Clinical Trial Update: A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating first-line sunitinib for advanced or metastatic Renal Cell Carcinoma in Asian patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: vghtpe user | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED